drugset / Trial / NCT01724242

Vaginal DHEA for Women After Breast Cancer

NCT01724242 ↗

Phase 2/3 Withdrawn Hadassah Medical Organization
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. DHEA, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.

Timeline

Start
2013-02
Primary completion
2014-01
Completion
2014-12

Outcome

Outcome not reported

Stopped (Enrollment): “Inability to recruit patients”

Drugs

EvaluationDrugModalityDoseRoute
Subject DHEA Unknown 6.5 mg Other